Interestingly, Djuzenova et al. (2019) showed that glioblastoma cells could be sensitized to an irradiation regimen with complementary MK-2206 medication, but this seemed to be limited to PTEN-wildtype tumor cells [9]. The gene discussed is PTEN; the disease is neoplasm.